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ABSTRACT
Like most solid tumors, glioblastoma multiforme (GBM) harbors multiple overexpressed and 
mutated genes that affect several signaling pathways.  Suppressing tumor growth of solid tumors 
like GBM without toxicity may be achieved by small molecules that selectively modulate a 
collection of targets across different signaling pathways, also known as selective 
polypharmacology. Phenotypic screening can be an effective method to uncover such 
compounds, but the lack of approaches to create focused libraries tailored to tumor targets has 
limited its impact.  Here, we create rational libraries for phenotypic screening by structure-based 
molecular docking chemical libraries to GBM-specific targets identified using the tumor’s RNA-
seq and mutation data along with cellular protein-protein interaction data. Screening of this 
enriched library of 50 candidates led to several active compounds. Among them 1 (IPR-2025), 
which (i) inhibited cell viability of low-passage patient-derived GBM spheroids with single-digit 
micromolar IC50s that are substantially better than standard-of-care temozolomide; (ii) blocked 
tube-formation of endothelial cells in Matrigel with sub-micromolar IC50s; and (iii) had no effect on 
primary hematopoietic CD34+ progenitor spheroids or astrocyte cell viability. RNA sequencing 
(RNA-seq) provided potential mechanism of action of 1 and mass spectrometry-based thermal 
proteome profiling (TPP) confirmed that the compound engages multiple targets. The ability of 1 
to inhibit GBM phenotypes without affecting normal cell viability suggests that our screening 
approach may hold promise for generating lead compounds with selective polypharmacology for 
the development of treatments of incurable diseases like GBM.
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Like most solid incurable tumors, glioblastoma multiforme (GBM) exhibit multiple 
hallmarks of cancer as delineated by Hanahan and Weinberg(1): Self-sufficiency in growth 
signals, insensitivity to growth inhibitory signals, evasion from programmed cell death (apoptosis), 
ability to undergo limitless cycles of cell growth, sustained ability to be supplied by blood 
(angiogenesis), and aggressive invasion of the brain parenchyma. Large-scale sequencing 
studies of human tumors such as The Cancer Genome Atlas (TCGA) project have revealed that 
the complex phenotypes that define cancer are driven by a large number of somatic mutations 
that occur in proteins across the cellular network(2). Whole genome sequencing studies that have 
profiled the molecular signatures of various cancers, such as in ovarian(3), colorectal(4), 
breast(5), renal(6), lung(7-9), pancreatic(10,11), and brain(12,13), have further confirmed that the 
complex phenotypes are driven by multiple targets spanning interconnected signaling pathways 
across the human protein-protein interaction network. 
Suppressing the growth and metastasis of solid tumors harboring tens of mutations 
without causing toxicity will require small molecules that selectively modulate multiple targets and 
signaling pathways. The identification of such compounds is a significant challenge, as most 
drugs that target multiple proteins are discovered in a retrospective manner. In some cases, drugs 
are developed to inhibit one target, but later, they are found to have additional targets(14). 
Metformin is one example of a drug that was developed to treat diabetes, but was later found to 
have beneficial effects in cancer likely due to off-targets of the drug(15). Drugs that were 
discovered either from natural products or phenotypic screens also often work through 
polypharmacology. One example is aspirin, which not only inhibits cyclooxygenases but also 
neutrophil activation and inducible nitric acid synthesis(16).
There has been a resurgence of interest in phenotypic screening in cancer drug 
discovery(17). Between 1999 and 2008, over half of FDA-approved first-in-class small-molecule 
drugs were discovered through phenotypic screening(18). The increased interest in phenotypic 
screening is due in part to the lack of effective treatment options for incurable tumors such as 
GBM, which remains the most aggressive brain tumor and responds poorly to standard-of-care 
therapy that includes surgery, irradiation, and temozolomide. Standard-of-care therapies for GBM 
have been essentially unchanged for decades with a median survival of only 14-16 months and 
a five-year survival rate of 3–5%(19,20). Ineffective tumor cell killing is largely due to intra-tumoral 
genetic instability which allows these malignancies to modulate cell survival pathways, 
angiogenesis, and invasion(21,22). In addition, the highly immunosuppressive GBM 
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microenvironment complicates therapeutic approaches that minimize tumor burden and promote 
host immunity(23-25). Moreover, investigations to date indicate therapies that combine TMZ with 
immunotherapy-based approaches can either promote or deplete immunity(26-29). Phenotypic 
screening can be an effective strategy for the development of small molecules to perturb the 
function of proteins that drive tumor growth and invasion. Despite the increased interest in 
phenotypic screening in cancer drug discovery, the main limitations of the approach include (i) 
the lack of methods to tailor library selection to the tumor genome, (ii) cellular assays that do not 
accurately represent a tumor, (iii) overreliance on immortalized cell lines, (iv) targeting a single 
protein when tumors are driven by multiple proteins, and (v) confining compound screening to 
one phenotype.
To date, most phenotypic screens are carried out on well-annotated tool compound 
libraries that include FDA-approved drugs. These are known as chemogenomic libraries, and they 
are used to uncover new biology for targets associated with these compounds or for drug-
repurposing purposes(30-33). However, existing approved drugs and tool compounds act on less 
than 5% of targets in the human genome(34). The lack of target diversity in chemogenomic 
libraries presents an opportunity for the development of new chemical libraries or for the 
enrichment of existing libraries. The creation of diverse libraries for high-throughput screening is 
a major challenge considering the vastness of chemical space. Just among commercially-
available compounds, there are now at least 400 million small organic compounds that can be 
purchased(35,36). In addition, specialized libraries designed using diversity-oriented synthesis 
(DOS)(37) and de novo combinatorial libraries such as SCUBIDOO(38) offer additional avenues 
to screen unexplored chemical space.
Traditional two-dimensional monolayer assays utilizing cancer cell lines have been the 
most practical method to phenotypically screen these large libraries. However, these screening 
campaigns have yielded compounds that fail to model compound efficacy and cytotoxicity in more 
disease-relevant assays(39). Traditional two-dimensional assays do not accurately capture the 
three-dimensional microenvironment of tumors, thus leading to toxic compounds that generally 
tend to block microtubule dynamics or lead to DNA modification(40,41). The use of immortalized 
cell lines to predict efficacy is now also recognized to be inadequate(42). There are now many 
examples of small molecules that are efficacious in traditional in vitro and in vivo models yet fail 
to show clinical efficacy(43). As a result, there has been intense interest in the development of 
more sophisticated three-dimensional assays. Cancer cells grown in three-dimensional spheroids 
are now widely used to investigate the effects of small molecules on tumor growth and other 
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endpoints such as invasion and remodeling of the tumor matrix. More sophisticated assays, such 
as spheroid and organoids, have been developed to better represent the tumor and its 
microenvironment.
Here we follow a rational approach to create chemical libraries that are used for phenotypic 
screening to generate small molecules with selective polypharmacology that inhibit GBM growth 
without affecting non-transformed normal cell lines. Our approach combines catalogs of 
differentially expressed molecular targets identified by tumor genomic profiles along with cellular 
protein-protein interaction data to select a collection of targets with druggable binding pockets. 
Approximately 9000 in-house compounds are docked to each of these targets. Small molecules 
that are predicted to simultaneously bind to multiple proteins are selected for phenotypic 
screening using three-dimensional spheroids of patient-derived GBM cells. Compounds were 
tested in non-transformed primary normal cell lines in (i) a three-dimensional assay using CD34+ 
progenitor cells and (ii) a two-dimensional assay using astrocytes. The effect of the compound on 
angiogenesis was also tested using a tube formation assay with brain endothelial cells. To 
uncover potential mechanisms of action, the compound was selected for RNA sequencing of 
compound-treated and untreated cells. Thermal proteome profiling was performed to identify 
potential targets. Cellular thermal shift assays using antibodies were used to confirm the binding 
of the compound to targets that emerged from the thermal proteome profiling study.
RESULTS
Target Selection, Virtual Screening, and Rank-Ordering of Chemical Library. A 
weakness of current implementations of phenotypic screening is the lack of rational approaches 
in the creation of chemical libraries. Here, we propose a strategy that uses the tumor’s genomic 
profile to enrich chemical libraries for phenotypic screening (Fig. 1a). The process begins with 
the identification of druggable pockets on a large number of protein structures obtained from the 
Protein Data Bank (PDB)(44). In previous work, we searched for druggable binding sites on 
proteins implicated in a range of cancers and classified them in the context of functional 
importance(45). Druggable binding sites were classified based on whether they occurred at a 
catalytic site (ENZ), a protein-protein interaction interface (PPI), or an allosteric site (OTH).
Using our approach, druggable binding sites were identified for GBM. Gene expression 
profiles were collected for GBM patients from TCGA. A total of 169 GBM tumors and 5 normal 
samples have been characterized using RNA sequencing platforms. The data were used to 
perform differential expression analysis to identify genes that are overexpressed in GBM (p < 
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0.001, FDR < 0.01, and log2 fold change (log2FC) > 1) (Fig. 1b). In addition, a set of somatic 
mutations was retrieved from GBM patients at TCGA and identified for 158 of the 169 tumor 
samples. In total, 755 genes with somatic mutations were overexpressed in GBM patient samples.
The set of 755 genes were subsequently filtered based on whether their protein products 
are involved in protein-protein interactions. Two large-scale protein-protein interaction networks 
of the human proteome were recently described by Rolland and co-workers(46). The first network 
is from literature curation of seven widely-used protein-protein interaction databases. The second 
network is based on systematically mapping human binary protein-protein interactions. The two 
protein-protein interaction datasets from both the literature-curated and experimentally-
determined networks were combined to form a large-scale protein-protein interaction network 
consisting of approximately 8000 proteins and 27000 interactions. The protein products of the 
genes implicated in GBM were mapped onto this protein-protein interaction network to construct 
a GBM subnetwork (Fig. 1c). Among the 755 previously-identified genes implicated in GBM, 390 
had at least one interaction in the network. In total, 117 of the 390 proteins had at least one 
druggable binding site (Fig. 1d and Table S1).
To identify small molecules that inhibit phenotypes associated with GBM, an in-house 
library of approximately 9000 compounds was docked to the set of 316 druggable binding sites 
on proteins in the GBM subnetwork. The Support Vector Machine-Knowledge Based (SVR-
KB)(47) scoring method was used to predict the binding affinities of each pair of protein-
compound interactions. The number of druggable binding sites with affinities better than a given 
SVR-KB cutoff was used to rank-order compounds (Fig. 1e). In this work, an SVR-KB cutoff 
corresponding to a computational binding affinity of 10 nM was used. Approximately 55 percent 
of compounds were predicted to bind to five or less binding sites, and 20 percent of the docked 
compounds were predicted to bind to none of the pockets in the GBM subnetwork (Fig. 1f). Less 
than 4 percent of the compounds were predicted to bind to at least 30 of the 316 binding sites. 
Small molecules with the highest number of predicted GBM targets were selected for further 
testing. A total of 154 compounds were selected for the first screen that were predicted to target 
between 38 and 86 binding sites on GBM-specific proteins. The mean number of predicted targets 
is 47 for the 154 compounds.  The top 154 compounds were clustered with hierarchical clustering 
using chemical similarity. For each cluster, the compound corresponding to the cluster center was 
selected for phenotypic testing (Table S2).
Exploring Compounds in Patient-Derived GBM Spheroids. A total of 47 compounds 
selected from the library of 9000 compounds were tested in a three-dimensional spheroid viability 
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assay(48,49) using the patient-derived primary glioma cell line GBM43(50) at 25 µM (Fig. 2a). 
Most compounds showed little to no effect on GBM43 cell viability, except for 1 (IPR-2025), which 
inhibited cell viability by 90% (Fig. 2b). The compound was resynthesized and its stability was 
tested following incubation in buffer (Fig. 2c). The compound was stable in buffer. A follow-up 
concentration-dependent study of 1 revealed an IC50 of 3.7 ± 0.1 µM in GBM43 (Fig. 2d and e). 
Compound 1 was tested in two additional glioblastoma spheroid models derived from different 
patients with recurrent GBM, namely GBM10 and SJ-GBM2. GBM10(50) is derived from an adult 
patient, while SJ-GBM2(51) is derived from a pediatric patient. The IC50 of 1 was 3.1 ± 1.5 µM 
and 2.9 ± 1.9 µM in GBM10 and SJ-GBM2, respectively. The effect of 1 on normal and non-
transformed cell viability was explored using CD34+ progenitor cells and astrocytes (Fig. 2d). Cell 
viability studies for CD34+ cells were performed using a colony formation assay, while a 
monolayer MTT assay was used for astrocytes. Compound 1 had no effect on the cell viability of 
CD34+ or astrocyte cells up to 100 µM. For the sake of comparison, the standard-of-care 
temozolomide inhibits GBM43 with an IC50 of 244 ± 24 µM(52). However, GBM43 is known to be 
moderately resistant to temozolomide(53). An alternative treatment option is the 
chemotherapeutic CCNU (lomustine), which inhibited GBM43 and GBM10 cell viability weakly, 
showing about 50% inhibition at 100 µM (Fig. 2f). It is important to note that the astrocyte assay 
is a 2-D assay, which is different than the 3-D assay used for the GBM cell viability studies, thus 
direct comparison of the exposure times between the two assays is not possible.  Cells grown in 
2-D are generally more sensitive to chemicals compared with cells grown in 3-D.  In 2-D, cells are
not in contact with each other, but they make contacts with the plastic surface, and adopt a
flattened morphology.  Cells in a 3-D environment, on the other hand, mimic the morphology of
cells found in tumors due to the fact that cells form contacts with other cells, triggering distinct
signaling pathways that makes them less sensitive to anti-tumor agents.  In addition, cells at the
center of spheroids experience hypoxia, which further enhances their survival, making them less
prone to cell killing by compounds.  Furthermore, in the 3-D environment found in spheroids,
compounds must be able to diffuse to access cells that are at the center of these spheroids, which
is often another mechanism of resistance, especially for compounds that are less likely to diffuse
into these spheroids due to their physico-chemical properties.
The activity of 1 was also assessed in three pancreatic ductal adenocarcinoma patient-
derived spheroid models(54-56): Pa02C, Panc10.05 (Pa16C), and Panc198 (Pa20C). Pa02C is 
from liver metastasis of pancreatic cancer, while Panc10.05 and Panc198 are from the primary 
pancreatic tumor. Compound 1 showed no activity in Pa02C and Panc198 and weak activity in 
Panc10.05 with an IC50 of 26.0 ± 5.9 µM IC50.
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Structure-Activity Relationship (SAR) of 1 (IPR-2025). A set of 5 analogs from our 
internal library were identified from commercial libraries with high Tanimoto similarity to 1 (Table 
S3): 2 (GFI-027), 3 (IPR-1909), 4 (RAG-021), 19 (IPR-2024), and 20 (KLM-017). These 5 
compounds were tested in a concentration-dependent manner in GBM43 (Fig. S1). Only 19 
inhibited in a concentration-dependent manner like 1, although the compound only reaches 60% 
inhibition at 100 µM in GBM10 and has an approximate IC50 of 33 µM and no effect in GBM43. 
An analog-by-catalog approach was followed to identify another 15 derivatives. These 
compounds were tested in GBM43 and GBM10 in a concentration-dependent manner (Fig. S1). 
Substitution of the fused tricyclic moiety in 14 (IPR-3440), 20 (KLM-17), and 21 (IPR-3442), 
among others, led to loss of activity. Among the derivatives that share the fused tricyclic moiety 
of the parent, two also feature the sulfonyl group on R1. 5 (IPR-3474) substitutes the toluene 
group on R1 with a biphenyl and lacks the carbonyl group on the pyrrolidinone group, while 6 (IPR-
3476) replaces the pyrrolidinone group with an amine linker. These two compounds suggest the 
importance of the carbonyl group on the pyrrolidinone in R1. Similarly, compounds that lack the 
sulfonyl group on R1, like 3, also lacked activity. 
To further assess the importance of the sulfonyl moiety, three additional compounds, 22 
(IPR-3502), 23 (IPR-3503), and 24 (IPR-3504), were synthesized that lack key moieties in R1 
(Fig. 3). The removal of the carbonyl group on the pyrrolidinone, sulfonyl linker, or both the 
sulfonyl linker and the methylbenzene group in 22, 23, and 24, respectively, led to loss of activity 
in both GBM43 and GBM10. Three additional derivatives were synthesized to add halogen groups 
to 1. Substitution of the methyl group in R3 with a trifluoromethyl in 25 (IPR-3593) resulted in 
nearly ten-fold decrease in IC50 across each of the GBM spheroids compared to 1. Chlorine atoms 
were added to two separate positions of the fused ring structure in 26 (IPR-3594) and 27 (IPR-
3595), resulting in no activity in either compound across the GBM spheroids. Among the 21 
analogs of 1 that were tested across each of the three GBM spheroids, only the trifluoromethyl 25 
resulted in measurable IC50s.
Compound 1 Inhibits Tube-Formation in Matrigel. Since the seminal work of 
Folkman(57), uncontrolled angiogenesis (the process of new blood vessel growth from existing 
ones) has become an established hallmark of cancer(1). Solid tumors require a dedicated blood 
supply once they reach a certain, limiting size, and antiangiogenic agents can block tumor growth 
by starving the tumor of oxygen and nutrients. A so-called “angiogenic switch” is an integral part 
of tumor development: varied tumor types secrete vascular endothelial growth factor (VEGF) and 
other proangiogenic stimuli and downregulate antiangiogenic proteins. There have also been 
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some promising clinical results with angiogenesis inhibitors in improving progression-free survival 
in both primary and recurrent GBM(58,59). This cancer is also characterized by microvascular 
proliferation(60) and high levels of VEGF(61). Given the ample evidence of the importance for 
angiogenesis in the biology of these tumors, there is significant need to identify novel compounds 
with specific antiangiogenic activity. The parent compound 1 was tested for its ability to inhibit 
tube formation of brain microvascular endothelial cells (Fig. 2g). Compound 1 inhibited tube 
formation with approximate 0.1 µM IC50 (Fig. 2h).  The effect of compound 1 on BMECs revealed 
an IG50 3.5 µM after a 48-hour exposure (Fig. S2). In comparison, pronounced effects on tube 
formation were seen at doses well below this, i.e. 100 nM and 1 µM (Fig. 2h). Moreover, the tube 
formation assay was conducted over a short term (8 hours), and as seen in the images in Fig. 
2g, there were no obvious signs of cell death at these concentrations.  
Structural Analysis and RNA Sequencing to Uncover Compound 1 Mechanism of 
Action. The binding modes of 1 to each of the targets predicted by the SVR-KB scoring function 
were examined in detail. Each target was classified using the structural context of the binding site 
and functional context of the protein (Table 1). Generally, the binding modes of 1 were at allosteric 
sites outside the active site on enzymes. Three allosteric sites were adjacent to known protein-
protein interaction interfaces on NCF2, NEDD4, and PYGL. Similarly, 1 was predicted to bind to 
allosteric sites adjacent to the active sites on KIF11 and TAP1. The compound was predicted to 
bind at pockets at the protein-protein interfaces at the PLK1 polo box and at the homodimers of 
NCF1 and PNP. The compound was also predicted to bind to the β-propeller structures of CDC20, 
GNB1, ITGA5, and RACK1.
RNA sequencing was performed on untreated GBM43 cells and GBM43 cells treated with 
10 µM 1 to validate the predicted targets of 1 and uncover a potential mechanism of action (Fig. 
4a). Differential expression analysis (p < 0.001, FDR < 0.01, |log2FC| > 1) revealed a set of 15 
overexpressed and 20 underexpressed genes in GBM43 cells treated with 1 (Fig. 4b). The sets 
of overexpressed and underexpressed were separately analyzed for overrepresented GO terms. 
No significantly overrepresented terms were found among either set of differentially expressed 
genes. The set of differentially expressed genes (DEGs) were compared with those known to be 
causally implicated in cancer using the Cancer Gene Census (CGC)(62). Two DEGs were 
previously identified as oncogenes. The transcription factor GATA2 has been shown to promote 
GBM progression through the EGFR/ERK/Elk-1 pathway(63). Similarly, the kinase KDR 
(VEGFR2) is a known oncogene in lung, blood, and skin cancers and plays a key role in regulating 
angiogenesis(64).
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The expression profile of cells treated with 1 was compared to the gene signatures of 
previously characterized compounds and gene knockdowns using the LINCS L1000 platform. The 
L1000 platform is an extension of the Connectivity Map (CMap) project(65), which used 
similarities in gene expression signatures to discover shared mechanisms of action between small 
molecule and genetic perturbations. The L1000 platform expands on CMap and uses a panel of 
approximately 1,000 landmark genes to characterize the molecular profiles of over 19,000 
compound and 5,000 gene perturbations across nine cell lines(66). To compare the gene 
expression profile of 1 to the existing signatures in L1000, a signature query was generated using 
the sets of overexpressed and underexpressed genes. The similarity between the signature query 
is compared with all other signatures in L1000 using a connectivity score (τ), which corresponds 
to the percentage of all reference gene sets that are more similar than the observed gene 
signature. The most similar 30 gene and small molecule perturbations of 1 are shown in Fig. 4c. 
The most similar gene signatures are gene knockdowns of GNA15 and OGFOD1. The G protein 
α-subunit GNA15 is part of the heterotrimeric G protein complex consisting of α-subunit and βγ 
complex, which mediate downstream signaling of G protein-coupled receptors (GPCRs)(67). 
While no α-subunits were among the targets predicted to bind to the compound, both the G protein 
β-subunit GNB1 and β-like subunit RACK1 were predicted targets of 1. RACK1 acts as a 
scaffolding protein in transcription regulation of the transcription factor EIF4E(68). Gene silencing 
and knockdown studies of RACK1 have resulted in promotion of apoptosis and inhibition of cell 
proliferation, migration, and invasion in glioma(69,70). The oxygenase OGFOD1 belongs to a 
family of transcriptional factor and chromatin regulators and has been found to inhibit cell 
proliferation in breast cancer cells(71). Also among the knockdown gene signatures most similar 
to the gene signature of 1 in L1000 are the tumor suppressors AES(72) and TP53BP2(73).
Thermal Proteome Profiling to Identify Potential Targets of 1 (IPR-2025). Once a 
compound is identified in a phenotypic screen, the challenge is to identify its targets. Several 
methods have been used in the past for target identification, such as biochemical, genomic, or 
computational approaches(74-77). Computational methods make use of statistical and machine 
learning methods to link a novel compound to existing compounds by identifying common features 
between the two. Previously developed algorithms have used similarities in compound 
scaffolds(78,79), protein structure similarity(80), side effects(81), and bioactivities(82) to infer a 
compound’s target. A more recent mass spectrometry-based method is thermal proteome 
profiling, which allows for systematic identification of a compound’s direct targets by analyzing 
shifts in melting temperature of the targets in cells(83,84). As a compound binds to its protein 
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target, the protein becomes more resistant to heat-induced unfolding and denaturation. This in 
turn increases the melting temperature of the protein.
Thermal proteome profiling was used to identify potential targets of 1. GBM43 cells were 
treated with 10 µM of 1 at six temperatures between 37 and 60 °C. Following heating, soluble 
proteins were extracted in phosphate-buffered saline (PBS) buffer, quantified and digested into 
peptides using trypsin. Digested peptides were analyzed by LC-MS/MS and quantified using 
label-free precursor-ion (MS1) intensity. The iBAQ values (intensities normalized by the size of 
the proteins) acquired after data analysis using MaxQuant(85) were used to fit thermal melting 
curves and to determine the shift in melting temperature between untreated and compound-
treated proteins (∆Tm). We acquired quantitative iBAQ data for over 1700 proteins across all 
temperatures at 1% FDR, of which the melting curves of 129 proteins were determined from the 
thermal profiling (Fig. 5a). A cutoff of 3 °C was used to identify proteins with significant thermal 
shifts when treated with 1. A total of 12 proteins were identified with ∆Tm ≥ 3 °C (Fig. 5b and S3). 
Interestingly, RACK1 was both predicted to be a target of 1 (Table 1) as well as showed a 
significant thermal shift in TPP. In contrast, a set of 7 proteins were identified to be destabilized 
when exposed to 1, resulting in a change in melting temperature ∆Tm ≤ -3 °C (Fig. 5c and S4). 
The largest observed destabilization was in DSTN, a component of the cytoskeleton.
Integrated Analysis of Computational, RNA-seq, and TPP Data for Potential 
Mechanisms of Action. To uncover the potential mechanism of action of 1, proteins predicted to 
bind 1 by SVR-KB, and proteins implicated by compound-specific changes by RNA-seq profiling, 
L1000 comparisons, and thermal proteome profiling were integrated into a protein network (Fig. 
5d). Proteins implicated from each of the four sources were connected based on structural and 
non-structural evidence using the STRING database(86). STRING incorporates protein-protein 
interactions from both direct physical interactions as well as indirect functional associations. 
Interactions come from a variety of sources, including experimental interactions from protein-
protein databases, pathway knowledge from manually curated databases, co-expression studies, 
and homology. Multiple interconnected modules are formed in the protein subnetwork. The largest 
module features proteins associated with the cell cycle (PPP1CB, PLK1, EXO1, and CDC20) and 
metabolism of compounds with nucleobases (KIF11, EXO1, TOP2A, and CENPE). Within this 
cluster, several targets were predicted to bind to 1, including EXO1, TOP2A, CENPE, and KIF11. 
Three proteins in this cluster showed positive thermal shifts, DCTN1, KIF5B, and PPP1CB, as 
well as a negative thermal shift in ARCN1. Both DCTN1 and KIF5B act as motor proteins: DCTN1 
is a subunit of dynactin, which binds to dynein and acts as cytoskeletal motors in cellular 
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transport(87), while KIF5B is a motor protein involved in mitosis and meiosis, and acts as a 
catalytic subunit of the tumor suppressors NF1 and NF2(88). Interestingly, upregulation of the 
dynactin mediator DYNC1I1 is observed in the RNA-seq analysis. A second interconnected 
module is formed by the G protein β-subunit and β-subunit-like proteins GNB1 and RACK1, 
respectively. The prediction of RACK1 as a direct target of 1 is supported by direct evidence from 
the thermal proteome profiling, as well as a similar stability shift in the RNA-binding protein 
HDLBP. Similarly, upregulation of the GPCR PTH2R and downregulation of the potassium 
channel KCNJ10, which belong to similar regulation pathways as GNB1, was also observed in 
the analysis of RNA-seq derived from treated versus non-treated GBM spheroids.
To confirm direct binding to RACK1, the effects of 1 and the inactive analog 22 were 
examined in a concentration-dependent manner with an antibody-based cellular thermal shift 
assay (CETSA) (Fig. 5e; top panel). Similar to thermal proteome profiling, GBM43 cells are 
treated with varying concentrations of the compound and then heated to 45 °C. Direct binding of 
the compound to the protein will result in protein stabilization and an increase in melting 
temperature. In GBM43, there is an increase in RACK1 abundance at 50 and 100 µM in cells 
treated with 1, suggesting that RACK1 may be among the targets of 1. To rule out non-specific 
binding of the compound, the assay was also performed on GAPDH, an enzyme involved in 
glycolysis, resulting in no difference in protein abundance with increase concentration of 
compound. When GBM43 were treated with the inactive analog 22, the concentration of the 
compound did not affect protein abundance compared to the DMSO control (Fig. 5e; bottom 
panel).
DISCUSSION
Tumors such as GBM exhibit multiple phenotypes that include uncontrolled growth, 
angiogenesis, invasion, and immune evasion. These phenotypes are driven by perturbations in 
genes and their protein products working in concert across multiple signaling pathways. The 
multiple targets involved in promoting tumor growth and metastasis pose a major challenge for 
the development of small-molecule therapeutic agents to treat these tumors. To date, the most 
common strategy in cancer drug discovery is to develop small molecules that modulate the 
function of a single target. This approach has not yielded therapeutic agents that are efficacious 
for complex tumors such as GBM. At the other extreme, phenotypic screening has been used to 
uncover novel anti-cancer agents(17). This strategy has led to several approved drugs, including 
eribulin in breast cancer, nelarabine in T-cell lympoblastic leukemia and lymphoma, and 
trametinib in metastatic melanoma(89). However, the limited diversity of chemical libraries, the 
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use of immortalized cell lines, and the reliance on two-dimensional cellular assays has mostly led 
to cytotoxic cell cycle inhibitors that have not yielded efficacy in patients(90).
A data-driven approach that combines genomic, structural, and protein-protein interaction 
data to enrich chemical libraries using computational docking has the potential to overcome the 
limitations of phenotypic screening for cancer drug discovery. Here, in a first proof-of-concept 
study, we propose a screening strategy that takes integrates vast orthogonal datasets including 
(i) tumor genomic data from patient-derived GBM samples available at TCGA, (ii) three-
dimensional structures of human proteins that enable the identification of druggable pockets in 
proteins implicated in GBM, and (iii) the large number of cellular protein-protein interactions that 
have been mapped over the past decade using yeast-two-hybrid and other methods. Specifically, 
our approach initially utilizes expression data from TCGA to select all genes that are 
overexpressed and mutated in GBM. The PDB is subsequently mined to retrieve available protein 
structures that are encoded by these genes. Druggable pockets within these structures are 
identified and used for structure-based screening to identify potential small-molecule inhibitors. 
Proteins that are known to be involved in protein-protein interactions and possess druggable 
pockets are used for structure-based docking of an in-house library of 9,000 compounds. The 
resulting protein-compound complexes were ranked to select 50 small molecules that bind to the 
highest number of GBM-specific proteins. The resulting compounds were tested in a cell viability 
assay utilizing patient-derived GBM cells grown in a physiologically relevant three-dimensional 
format. Our strategy has a significant advantage over standard phenotypic screening, namely that 
large libraries containing thousands of compounds can be enriched to select a small collection of 
candidates that can be tested in more sophisticated assays and multiple phenotypes. Two assays 
are used, spheroid growth and tube formation assay in Matrigel. We also strictly use patient-
derived low-passage cell lines to overcome the limitations of existing phenotypic screens that are 
done on established cell lines. In addition to using GBM cancer cell lines, we also employ low 
passage pancreatic ductal adenocarcinoma cell lines as well as normal non-transformed cells 
such as CD34+ progenitor cells and astrocytes.
Compound collections were initially screened at a single concentration in duplicate using 
GBM43 cells grown in 3D spheroids. In the set of compounds that were predicted to maximally 
bind to GBM-specific targets, one compound, namely 1 (IPR-2025), showed substantial inhibition 
of cell viability. A concentration-dependence study revealed that 1 (IPR-2025) showed high 
potency in all three patient-derived GBM cell lines with IC50s < 4 µM. The compound was tested 
for its effect on tube formation in Matrigel, an indication of their potential usefulness in blocking 
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angiogenesis and a key feature of GBM tumors, inhibiting with sub-micromolar IC50. The 
compound was tested in both normal non-transformed human CD34+ progenitor cells and primary 
brain astrocytes. Significantly, 1 had no effect on colony formation of CD34+ cells or astrocyte cell 
viability suggesting that there is a therapeutic window. To put the activity in perspective, standard-
of-care temozolomide inhibits GBM43 growth with an approximate IC50 of 250 µM, consistent with 
the high therapeutic doses used in GBM.
RNA-seq was initially employed to uncover a potential mechanism of action for 1 in 
GBM43. Compound 1 exhibited high selectivity as relatively few genes were affected by this 
compound. The L1000 platform was employed to identify gene knockdowns that led to a similar 
effect on gene expression. However, L1000 utilizes adherent cell cultures and established cell 
lines in cancers other than GBM. In contrast, GBM43 is a low-passage patient-derived cell line 
grown as a spheroid model and is expected to have a different underlying gene expression profile. 
Interestingly, the expression profile of 1 was most similar to the knockdown of G protein GNA15, 
which belongs to the same family as the predicted target GNB1 and structural homolog RACK1.
Considering the GBM-specific activity of 1 (IPR-2025) and its lack of cytotoxicity in normal 
non-transformed cell lines, thermal proteome profiling was used to identify potential targets of this 
compound. TPP uncovered up to 11 potential targets of 1, including RACK1 and KIF5B. It is 
interesting that among them, one target (RACK1) was also among the targets of 1 that emerged 
from the structure-based docking and ranking analysis. Analysis of the predicted binding mode 
reveals that the compound may bind within the central tunnel of the β-propeller structure. Follow-
up CETSA analysis seems to support the fact that 1 may bind to RACK1 directly in cell culture. It 
is important to note that the TPP list is likely not a comprehensive list of all direct targets of 1, and 
it is also likely that the 20 top targets identified in TPP may not be all targets of 1.  Furthermore, 
RACK1 is a scaffold protein that is engaged in multiple protein-protein interactions by creating a 
large multi-protein complex.  Even if we were able to confirm RACK1 direct binding, it would not 
establish that the compound inhibits RACK1 protein-protein interactions.  Also, it is worth noting 
that the compound was designed to selectively bind to multiple targets.  It is possible that the 
biological response that is observed as a result of treatment with compound is the result of binding 
of the compound to other targets. Further mechanistic studies beyond the scope of this 
manuscript will have to be performed to establish the exact mechanism of this compound.
Several derivatives of compound 1 either from commercial sources or from our own 
synthesis were tested for inhibition of cancer cell viability. Ultimately, identification of all targets 
will be required to better explain the observed SAR. However, structure-activity analyses can be 
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performed using the chemical structure of compounds and their biological activity.  Compounds 
2-21 were obtained from commercial sources through a substructure search.  They may share
structure with 1, but they have key differences that makes them in active.  For example,
compounds 7-18 and 20-21 lack the dibenzofuran group of 1.  This group appears to be critical
for biological activity. In fact, slight modifications at this moiety, such as introduction of chlorine
atoms in compounds 26 and 27 led to complete loss of activity.  While compounds 2-6 and
compound 19 have the dibenzofuran moiety, they are substantially different in structure and lack
the critical N-acylsulfonamide core.  Compounds 22-24 were designed to explore the importance
of the N-acylsulfonamide on compound 1.  N-acylsulfonamides are known to react with
nucleophiles such as serine residues.  The N-acylsulfonamide moiety of compound 1 could
possibly react with serine, threonine, or tyrosine nucleophiles as illustrated in Fig. S5. Replacing
the N-acylsulfonamide carbonyl with methylene to generate 22 resulted in complete elimination
of compound activity.  A similar observation was made when the sulfone was replaced with
methylene in compound 23. We wondered if the product compound (Fig. S5) following
nucleophilic attack of the N-acylsulfonamide is behind the biological activity of compound 1.
Compound 24 showed no activity, suggesting that a combination of binding and covalent
modification is likely behind the activity of compound 1.  However, the fact that subtle
modifications to other parts of the compound, such as introduction of chlorine atoms in 26 and
27, led to substantial loss in activity, suggests that the biological activity of compound 1 is a
combination of binding and covalent modification.
In summary, we implement a multi-target screening approach that integrates cancer 
genomics with the druggable protein interactome to identify therapeutic candidates of GBM. The 
strategy of selecting compounds that were predicted to either target the highest number of GBM-
specific proteins yielded a candidate compound. We pursued the compound in RNA-seq to 
discover potential mechanisms of action. Thermal proteome profiling of 1 revealed possible 
targets, including the computational predicted target RACK1. The ability of 1 to selectively target 
GBM phenotypes without affecting normal cell viability makes it suitable as a lead compound to 
uncover new targets in GBM and to develop potential therapeutic agents with multi-targeting 
properties.
MATERIALS AND METHODS
Cell Culture. The SJ-GBM2 cell line was obtained from the Children’s Oncology Group. 
The GBM10 and GBM43 xenografts were a kind gift from Dr. Jann Sarkaria (Mayo Clinic), and 
tumors were expanded by passage in the flank of NOD/SCID γnull mice. To generate GBM10 and 
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GBM43 cell lines, tumors were harvested, disaggregated, and maintained in 2.5% FBS for 14 
days on Matrigel-coated plates (BD Biosciences) to remove murine fibroblasts as previously 
described (50). Cell lines were propagated in DMEM with 10% FBS medium with glutamine 
(Cellgro, Manassas, VA) for no more than 7 passages in 5% CO2 at 37 °C. Cell line identity was 
confirmed by DNA fingerprint analysis (IDEXX BioResearch) for species and baseline short-
tandem repeat analysis testing.  The pancreatic cancer cells used in these studies were low-
passage patient-derived PDAC cell lines (fewer than 35 passages from patient tumors) and that 
were received from Dr. Anirban Maitra (The Johns Hopkins University) and maintained as 
previously described (55,91). Pa02C, Panc10.05, and Panc198 were cultured in DMEM medium 
and supplemented with 10% FBS in 5% CO2 at 37 °C for fewer than 10 passages. Cell line identity 
was confirmed by DNA fingerprint analysis (IDEXX BioResearch) for species and baseline short-
tandem repeat analysis testing and cells were routinely checked for mycoplasma.
GBM and PDAC 3D models. GBM10, GBM43, and SJ-GBM2 spheroids were generated 
by plating early-passage cells at 2.5 × 104 cells per well in 96-well ultralow attachment plates 
(Corning Inc.) in DMEM/F12 (1:1; GIBCO) supplemented with 2% B27 supplement (GIBCO), 20 
ng/mL epidermal growth factor (EGF), and 20 ng/mL fibroblast growth factor (FGF) (Peprotech) 
for 2 days. The spheroids were then treated with compounds and growth analyzed by Alamar 
blue staining at day 5 following compound exposure as previously described by our group (52). 
Astrocyte cell proliferation was determined by The CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay (MTS) (Promega) performed in 96-well plates. Primary human fetal astrocytes 
were purchased from ABM (cat #T4033) and cultured in progenitor astrocyte growth media 
defined by Barris and co-workers (92).  Cells were seeded at 8 × 103/well in DMEM medium with 
10% FBS and 1% 100X Penicillin/Streptomycin. Cell numbers were determined after 3 days of 
incubation with DMSO or compounds at indicated concentrations. 20 μL of MTS solution was 
added to the well. After 1 hour incubation at 37 °C, the absorbance was measured at 490 nm. 
Experiments were done in triplicate.
PDAC cells were grown as tumor spheroids as described previously using pancreatic 
cancer cells stably transduced with TdTomato (red) and the intensity of the spheroids over time 
was quantitated as described in our previous studies (56,91,94). Briefly, PDAC cells (1,000 
cell/well) were seeded in ultralow adherence 96-well plates (Corning Inc.) in media containing 3% 
reduced growth factor Matrigel (Corning Inc.) and 5% FBS. Spheroids were fed or treated on days 
4 and 8.  Red fluorescence intensity was measured at day 12 following plating using the Thermo 
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ArrayScan (Thermo Fisher Scientific). Percent viability for drug-treated wells was quantitated 
compared to media control. 
Half maximal inhibitory concentration (IC50) of cell viability curves were determined using 
a four-parameter logistic model (93). IC50 values represent relative IC50s, that is, the minimum 
parameter of the model is the lowest cell viability observed. Cell viability curves were determined 
using the non-linear least-squares method as implemented in the SciPy package in Python.
Colony-forming Unit (CFU) Assay.  Briefly, purified human umbilical cord blood CD34+ 
cells were obtained from the Angio BioCore (IUSCC) and the IC50 values determined by dose 
response curves. CD34+ cells were incubated with compounds and plated in the presence of the 
compounds at 2 × 103 cells per 35 mm dish in MethoCult H4434 (Stemcell Technologies) as 
previously described (95). The number of clonogenic progenitor colonies was enumerated under 
a light microscope at day 14 post-compound exposure.
TCGA GBM Gene Expression and Somatic Mutations. RNA-sequencing and mutation 
data from GBM were identified from The Cancer Genome Atlas (TCGA) project(12,96) and 
collected from the National Cancer Institute’s Genomic Data Commons (GDC) data portal(97). As 
part of the GDC pipeline, 169 tumors and 5 normal samples were previously aligned against the 
GRCh38 genome assembly using STAR 2-pass (98) and quantified using HTSeq (99). Level 3 
HTSeq fragment counts were collected from all 174 samples and used these as read counts for 
differential expression analysis. Differentially expressed genes were identified using the 
edgeR(100) package and the quasi-likelihood F-test pipeline (101) for hypothesis testing. A 
counts-per-million (CPM) threshold corresponding to a library count of 10 (CPM ≈ 0.15) was used 
to filter out genes with low reads. Overexpressed genes were defined as those with p < 0.001, 
FDR < 0.01, and log2 fold change (log2FC) > 1. Ensembl Gene identifiers from the differential 
expression analysis were mapped to UniProt(102) identifiers using BioMart(103). Open-access 
mutation annotation format (MAF) files for GBM were also collected from the GDC data portal. 
The GDC pipeline used the MuTect2(104) pipeline for mutation calling. As part of the GDC’s 
workflow, low quality and potentially germline variants were removed. Somatic mutations were 
mapped to their corresponding proteins using the UniProt ID.
Protein-Protein Interaction Network. Rolland and associates (46) recently constructed 
two large-scale protein-protein interaction networks. The first is based on literature curation and 
benchmarking of seven protein-protein interaction databases, producing a network of 
approximately 5500 proteins and 12000 interactions. The second is based on systematic 
Page 23 of 59






























































experimental testing of pairwise combinations of approximately 13000 genes and describes a 
network of approximately 4200 proteins and 14000 interactions. Entrez genes were mapped to 
UniProt identifiers using UniProt’s mapping tool (http://www.uniprot.org/mapping/) and these two 
networks were combined together using the NetworkX (105) module in Python. The resulting 
protein-protein interaction network consists of approximately 27000 interactions across 8000 
proteins and was visualized using Cytoscape (106) (v3.3.0).
Druggable Binding Sites. In a previous work, a set of druggable binding pockets were 
identified in the human proteome and explored in the context of functional importance, signaling 
pathways, and the human interactome(45). In brief, a set of 4124 proteins were identified in the 
human proteome that have been solved with crystallography. Druggable binding pockets were 
found on these proteins using the SiteMap(107,108) module in Schrödinger (Schrödinger LLC, 
New York, NY). Up to 10 binding sites were mapped for each structure. Each binding site was 
evaluated by its ability to bind a ligand (SiteScore) and its druggability (DrugScore). Only binding 
sites with SiteScore and DrugScore above 0.8 were kept. In total, 5498 binding sites on 2607 
proteins were found. Each binding site identified by SiteMap was visually inspected and manually 
annotated to determine its functional role in the protein. If an active site residue was in contact 
with the SiteMap spheres, or if a catalytic molecule or inhibitor occupied the space of the spheres, 
the binding site was labeled ‘enzyme’ (ENZ). If the binding site was at a protein-protein interaction 
(PPI) interface on the original structure or on any of the aligned structures, the binding site was 
labeled ‘PPI’. Otherwise, if the binding site was neither enzyme nor part of the interaction 
interface, it was labeled ‘other’ (OTH).
Virtual Screening GBM Network. The set of druggable binding sites on proteins which 
were (i) overexpressed in GBM, (ii) featured somatic mutations in GBM, and (iii) were part of the 
PPI interactome were selected. Specifically, we focused on binding sites that were classified as 
either PPI or OTH and omitted those with solely ENZ classifications. In total, 316 binding sites 
were identified. The set of binding pockets were docked against an internal chemical library of 
small molecules. These compounds are from previous screening campaigns primarily focused on 
targeting tight protein-protein interactions. Compounds possessing pan-assay interference 
compound (PAINS)(109) or rapid elimination of swill (REOS)(110) moieties were discarded. This 
resulted in a compound library of 9075 small molecules and their enantiomers. Compounds were 
docked against 316 binding sites on proteins implicated in GBM using AutoDock Vina(111) 
(v1.1.2). The average coordinates of the SiteMap spheres were used to identify the centroid of 
the binding site for docking. Each binding site was represented as a box with dimensions of 21 Å 
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× 21 Å × 21 Å. All other parameters were set to default values. Docked poses were rescored using 
the previously developed Support Vector Machine-Knowledge Based (SVR-KB)(47) scoring 
function. In this scoring function, knowledge-based pair-potentials of co-crystal complexes are 
used to train a regression model to predict the binding affinity of docked complexes. To rank-order 
compounds, the number of pockets with binding affinities better than a given SVR-KB cutoff for 
that compound were counted. Here, an SVR-KB cutoff corresponding to a predicted binding 
affinity of 10 nM was used. Compounds were rank-ordered using the number of binding sites 
predicted to bind to the compound with an affinity better than the SVR-KB cutoff. The top 154 
compounds were retrieved and clustered using the Canvas module in Schrödinger. A hashed 
binary fingerprint corresponding to atom triplets of Daylight invariant atom types were generated 
for the selected compounds. Compounds were hierarchically clustered using their atom triplet 
fingerprints and average linkage clustering to 50 clusters. The Tanimoto similarity between a pair 
of fingerprints was used as the distance metric. Compounds corresponding to the centroid of each 
cluster were selected for experimental validation. 
Tube Formation Assay. The Matrigel based tube formation assay was performed as 
previously described (112). Briefly, 50 µL Matrigel (Corning, Corning, NY) was allowed to solidify 
in a 96 well black, clear bottom plate at 37 °C for 20 min. Primary brain microvascular endothelial 
cells (BMECs; Cell Systems, Seattle, WA) were added to the solid Matrigel at 15,000 cells per 
well in 100 µL endothelial growth medium-2 (EGM-2, Lonza, Walkersville, MD) and dosed with 
appropriate concentrations of compound with 1 µL DMSO per well. Tube formation was observed 
every 2 hours by brightfield microscopy and images were taken after 8 hours of tube formation. 
Six images per treatment were analyzed with the Angiogenesis Analyzer plugin for ImageJ(113), 
and BMEC total tubule length for treated cells was normalized to DMSO-treated samples. 
Statistical analysis using one-way ANOVA with Dunnett’s post hoc test to compare treatments 
with DMSO control was completed using GraphPad Prism (v7.0, GraphPad Software, La Jolla, 
CA).
RNA-Seq of Compound-Treated Cells. GBM43 cells were treated with 10 µM 1 (IPR-
2025). RNA-seq analysis was conducted in triplicates for the untreated control and 1. After 
compound treatment, GBM43 cells were collected and rinsed with 1× PBS. The pellet was first 
homogenized in RLT lysis buffer plus β-mercaptoethanol and total RNA was extracted with 
RNeasy Mini Kit (Qiagen) in combination with QIAshredder (Qiagen). The RNA quality was 
assessed by A260/A280 ratio (NanoDrop) and stored at -80 °C.
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Total RNA was evaluated for its quantity and quality using the Agilent Bioanalyzer 2100 
system. For RNA quality, a RIN number of 7 or higher was desired. A total of 500 ng RNA was 
used. The cDNA library was prepared through mRNA purification and enrichment, RNA 
fragmentation, cDNA synthesis, ligation of index adaptors, and amplification, following the TruSeq 
Stranded mRNA Sample Preparation Guide, RS-122-9004DOC, Part# 15031047 Rev. E 
(Illumina, Inc.). Each resulting indexed library was quantified, and its quality accessed by Qubit 
and Agilent Bioanalyzer, and multiple libraries pooled in equal molarity. Five µL of 2 nM pooled 
libraries per lane was then denatured, neutralized, and applied to the cBot for flow cell deposition 
and cluster amplification, before loading to HiSeq 4000 for sequencing (Illumina, Inc.).
The RNA-seq aligner from STAR(98) (v2.5) was used to map RNA-seq reads to the human 
reference genome (hg38), with the following parameter: ‘--outSAMmapqUnique 60’. Uniquely 
mapped sequencing reads were assigned to genes using featureCounts(114) (from subread 
v1.5.1) with the following parameters: ‘-s 2 -Q 10’. The genes were filtered for further analysis if 
their count per million (CPM) of reads was less than 0.5 in more than 4 samples. The method of 
trimmed mean of M values (TMM) was adopted for gene expression normalization cross all 
samples, followed by differential expression (DE) analysis between different conditions using 
edgeR(100,115) (v3.20.8).
Differentially expressed genes (DEG) were determined using p-value and false discovery 
rate (FDR) cutoffs of 0.001 and 0.01, respectively. A fold change (|log2FC|) cutoff of 1 was used. 
The functional analysis was performed on overexpressed and underexpressed DEGs separately 
with a cutoff of FDR < 0.05 to identify significantly overrepresented Gene Ontology (GO) and/or 
KEGG pathways using DAVID(116,117) and PANTHER(118).
Thermal Proteome Profiling. GBM43 cells were trypsinized, washed with PBS, and 
suspended in PBS supplemented with a protease inhibitor cocktail (Sigma‐Aldrich). Suspended 
cells were treated with 10 µM 1 (IPR-2025) or DMSO for 1 hour at 37 °C, then the treated cells 
were separated into fractions, each with 5 × 106 cells for proteome thermal profiling. Fractions 
were heated for 3 min to the following temperatures: (i) 37 °C, (ii) 40 °C, (iii) 45 °C, (iv) 50 °C, (v) 
55 °C, and (vi) 60 °C, then incubated for 3 min at room temperature and frozen in liquid nitrogen. 
Samples were lysed with three freeze-thaw cycles using liquid nitrogen and 25 °C water bath. 
Cell lysates were centrifuged at 100,000 × g for 20 min at 4 °C to separate protein aggregates 
from soluble proteins. Supernatants were collected for LC-MS/MS.
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Protein concentration in each sample was determined by bicinchoninic acid (BCA) assay 
with BSA as a standard. About 50 µg protein from each sample was denatured by adding 50 µL 
of 8M urea, reduced by incubating with 10 mM dithiothreitol (DTT) at 50 °C for 45 min, and 
cysteine alkylated with 20 mM iodoacetamide (IAA) in the dark for 45 min at room temperature, 
followed by incubation with 5 mM DTT for 20 min at 37 °C to scavenge residual IAA. Proteins 
were digested using sequencing grade trypsin and Lys-C mix from Promega at a 1:25 (w/w) 
enzyme-to-protein ratio at 37 °C overnight. The digested peptides were cleaned using C18 silica 
micro spin columns (The Nest Group Inc.) and peptides were eluted using 80% acetonitrile 
containing 0.1% formic acid (FA). The samples were vacuum dried and re-suspended in 3% 
acetonitrile and 0.1% formic acid. The peptide concentration was determined by BCA assay with 
BSA as a standard. Peptides concentration was adjusted to 0.2 µg/µL, soluble and insoluble 
samples were mixed together and 5 µL was used for LC-MS/MS analysis as described below.
Samples were analyzed by reverse-phase LC-ESI-MS/MS system using the Dionex 
UltiMate 3000 RSLCnano System coupled to the Q Exactive High Field (HF) Hybrid Quadrupole-
Orbitrap MS and a Nano-electrospray Flex ion source (Thermo Fisher Scientific). Peptides were 
loaded onto a trap column (300 µm ID  5 mm) packed with 5 µm 100 Å PepMap C18 medium, 
and then separated on a reverse phase column (15 cm long × 75 µm ID) packed with 3 µm 100 
Å PepMap C18 silica (Thermo Fisher Scientific). All the MS measurements were performed in the 
positive ion mode, using 120 min LC gradient as previously described(119). The mass 
spectrometer was operated using standard data-dependent mode. MS data were acquired with a 
Top20 data-dependent MS/MS scan method. The full scan MS spectra were collected in the 400-
1,600 m/z range with a maximum injection time of 100 milliseconds, a resolution of 120,000 at 
200 m/z, spray voltage of 2 and AGC target of 3 × 106. Fragmentation of precursor ions was 
performed by high-energy C-trap dissociation (HCD) with the normalized collision energy of 27 
eV. MS/MS scans were acquired at a resolution of 15,000 at m/z 200 with an ion-target value of 
1 × 105 and a maximum injection of 20 milliseconds. The dynamic exclusion was set at 15 s to 
avoid repeated scanning of identical peptides. Instrument was calibrated at the start of each batch 
run and then in every 72 hours using calibration mix solution (Thermo Scientific). The performance 
of the instrument was also evaluated routinely using complex E. coli digest purchased from 
Sigma.
Raw LC-MS/MS data were analyzed using MaxQuant(85) (v1.6.0.16) against the UniProt 
human protein database containing 40,707 proteins. The database search was performed with 
the precursor mass tolerance set to 10 ppm and MS/MS fragment ions tolerance was set to 20 
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ppm. Database search was performed with enzyme specificity for trypsin and LysC, allowing up 
to two missed cleavages. Oxidation of methionine and N-terminal acetylation were defined as a 
variable modification, and carbamidomethylation of cysteine was defined as a fixed modification 
for database searches. The ‘unique plus razor peptides’ were used for peptide quantitation. The 
false discovery rate (FDR) of both peptides and proteins identification was set at 0.01. Data were 
searched with ‘match between runs’ option. In the case of identified peptides that are shared 
between two proteins, these were combined and reported as one protein group. Proteins 
matching to the reverse database were filtered out.
Protein abundances were quantified using iBAQ(120) and transformed into relative 
concentrations relative to the lowest temperature (37 °C). Protein fold changes were normalized 
and melting curves were fitted following the protocol described by Savitski(83), Franken(84), and 
co-workers. The previously described normalization protocol(83) was adapted to fit the range of 
temperatures in our experiments. Melting curves were selected from both the vehicle and 
treatment groups where the fold change at 55 °C was between 0.4 and 0.6 and the fold change 
at 60 °C was less than 0.4. Normalization was then applied as previously described(83). Following 




― (𝑎𝑇 ― 𝑏)
+ 𝑝
where  is the temperature,  and  are constants, and  is the plateau as . The 𝑇 𝑎 𝑏 𝑝 𝑇→∞
melting point  is found using:𝑇𝑚
𝑇𝑚 =
𝑎
𝑏 ― ln (1 ― 𝑦𝑦 ― 𝑝)
at . The slope of the melting curve  is found at the 𝑓(𝑇𝑚) = 𝑦 = 0.5 𝑠𝑙𝑜𝑝𝑒 = 𝑓′(𝑇𝑖𝑛𝑓𝑙𝑒𝑐𝑡𝑖𝑜𝑛)
inflection point  where . Melting curves were determined using the non-𝑇𝑖𝑛𝑓𝑙𝑒𝑐𝑡𝑖𝑜𝑛 𝑓′′(𝑇𝑖𝑛𝑓𝑙𝑒𝑐𝑡𝑖𝑜𝑛) = 0
linear least-squares method as implemented in the SciPy package in Python. Proteins with poorly 
fitted curves were excluded if the parameters of the curve fit any of the following criteria: (i) vehicle 
or treatment curve with , (ii) vehicle , (iii) the number of points between 𝑅2 <  0.8 𝑝𝑙𝑎𝑡𝑒𝑎𝑢 > 0.3
, and (iv) vehicle or treatment . In total, 129 proteins were (𝑝𝑙𝑎𝑡𝑒𝑎𝑢 + 0.1, 0.9) < 1 𝑠𝑙𝑜𝑝𝑒 > ―0.06
identified that passed all quality control filters. The shift in melting point was determined as:Δ𝑇𝑚 
Δ𝑇𝑚 = 𝑇treatment𝑚 ― 𝑇vehicle𝑚
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A cutoff of  was used to identify proteins with significant thermal stability following Δ𝑇𝑚 ≥ 3.0
compound treatment.
Gene Set Analysis. The STRING (Search Tool for the Retrieval of Interacting 
Genes/Proteins) database(86) incorporates protein-protein interactions from both direct physical 
interactions as well as indirect functional associations. STRING was used to integrate gene sets 
identified from protein target prediction using SVR-KB, differentially expressed genes identified 
from RNA sequencing, most similar gene signatures from L1000, and genes identified by thermal 
proteome profiling. A concatenated list of all HUGO gene symbols was used as input. 
Connections coming from text mining sources were excluded. Edges with confidence score < 0.7 
(high confidence) and genes with no edges in the subnetwork were excluded. The resulting 
subnetworks were visualized using Cytoscape(106).
General Chemistry. Preparative thin layer chromatography (PTLC) was performed on 20 
× 20 cm plates (500-micron thick silica gel). Silica gel chromatography was performed on a 
Biotage Horizon flash chromatography system. 1H NMR spectra were recorded on a Bruker 
Ascend TM 400 spectrometer at 400 MHz at 298 K, and the chemical shifts are given in parts per 
million (ppm) referenced to the residual proton signal of the deuterated solvents: CHCl3 at δ = 
7.26 ppm and CH3OH or CH3OD at δ = 3.30 ppm. LC-MS spectra were taken on an Agilent 
Technologies 1260 Infinity or 6120 Quadrupole spectrometer. The mobile phase for the LC was 
acetontrile (A) and water (B) with 0.01% formic acid, and the eluent gradient was from 5-95% A 
in 6.0 min, 60-95% A in 5.0 min, 80-100% A in 5.0 min and 85-100% A in 10 min using a SBC18 
50 mm × 4.6 mm × 2.7 μm capillary column. Mass spectra (MS) were measured by electrospray 



























tert-butyl 5-oxo-1-tosylpyrrolidine-2-carboxylate (1a). To a solution of tert-butyl 5-
oxopyrrolidine-2-carboxylate (530 mg, 2.86 mmol, 1.0 eq) in anhydrous THF (10 mL) at 0 °C, NaH 
(343 mg, 8.58 mmol, 3.0 eq) was added. The mixture was stirred for 15 min, and 4-
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methylbenzene-1-sulfonyl chloride (600 mg, 3.15 mmol, 1.1 eq) was added. The reaction mixture 
was stirred at room temperature for 2.5 h. Water was added and the mixture was extracted with 
EA. The organic phase was washed with water, brine, and dried over Na2SO4. It was filtered and 
concentrated to give the desired product (0.7 g). 1H NMR (400 MHz, CDCl3): δ 7.97 (d, J = 8.4 
Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 4.81 – 4.66 (m, 1H), 2.60 – 2.49 (m, 1H), 2.43 (s, 3H), 2.42 – 
2.35 (m, 2H), 2.09 – 2.01 (m, 1H), 1.50 (s, 9H). LC-MS (m/z) = 340 [M+H] +.
5-oxo-1-tosylpyrrolidine-2-carboxylic acid (1b). TFA (2.0 mL) was added to a solution 
of 1a (0.7 g, 2.06 mmol, 1.0 eq) in DCM (10.0 mL), and the mixture was stirred at room 
temperature for 2.0 h. The solution was concentrated to give a crude product (0.5 g). LC-MS (m/z) 
= 284 [M+H]+.
N-(2-methoxydibenzo[b,d]furan-3-yl)-5-oxo-1-tosylpyrrolidine-2-carboxamide (1). 
To a solution of 1b (75 mg, 0.26 mmol, 1.0 eq) and 2-methoxydibenzo[b,d]furan-3-amine (56 mg, 
0.26 mmol, 1.0 eq) in pyridine (2.0 mL), POCl3 (10 drops) was added. The mixture was stirred at 
65 °C overnight. Water was added, and the mixture was extracted with EA. The organic phase 
was washed with water, brine, and dried over Na2SO4. It was filtered and concentrated. The 
residue was purified with prep-TLC to give the desired product (30 mg). 1H NMR (400 MHz, 
CDCl3): δ 8.66 (s, 1H), 8.54 (s, 1H), 7.93 (d, J = 8.4 Hz, 2H), 7.88 (d, J = 7.6 Hz, 1H), 7.57 (d, J 
= 8.2 Hz, 1H), 7.46 – 7.40 (m, 2H), 7.33 (t, J = 7.5 Hz, 1H), 7.28 (d, J = 8.4 Hz, 2H), 4.96 – 4.91 
(m, 1H), 4.05 (s, 3H), 2.81 (dt, J = 20.4, 8.7 Hz, 1H), 2.51 – 2.40 (m, 5H), 2.34 (t, J = 10.0 Hz, 























TsCl TEA LiOH THF/H2O
Methyl 1-tosylpyrrolidine-2-carboxylate (22a). In an oven-dried round-bottom flask, 
methyl pyrrolidine-2-carboxylate (500 mg, 3.02 mmol) was taken in DCM (10 mL) at 0 °C. To that 
solution Et3N (915 mg, 9.06 mmol) was added dropwise over a period of 10 min. After a few min 
of stirring at same temperature, TsCl (575 mg, 3.02 mmol) was added portion-wise and reaction 
mixture was slowly brought to room temperature over a period of 2 hour (TLC showed the 
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complete consumption of starting materials). The resulting mixture was extracted with DCM (3 × 
20 mL) and the organic layers were combined and washed with brine (30 mL). The organic phase 
was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was 
applied onto a silica gel column with PE/EA (1:1) to afford the desired product (750g, 88% yield) 
as white solid. LC-MS (m/z) 284.1 [M+H]+.
1-Tosylpyrrolidine-2-carboxylic acid (22b). To a solution of 22a (100 mg, 0.353 mmol)
in THF/H2O (4 mL:1 mL), LiOH (30 mg, 0.707 mmol) was added. The resulting solution was stirred 
overnight at room temperature. The pH of the reaction solution was adjusted to a weak acidity 
with 1N hydrochloric acid. The resulting mixture was extracted with ethyl acetate (3 × 20 mL) and 
the organic layers were combined and washed with brine (30 mL). The organic phase was dried 
over anhydrous sodium sulfate and concentrated under vacuum. The residue was the desired 
product (100 mg crude) as white solid. LC-MS (m/z) 270.3 [M+H]+.
N-(2-Methoxydibenzo[b,d]furan-3-yl)-1-tosylpyrrolidine-2-carboxamide (22). Into a 
50 mL round-bottom flask purged was placed a solution of 22a (63 mg crude, 0.235 mmol) in 
DCM (3 ml), and then DIEA (91 mg, 0.704 mmol), 2-methoxydibenzo[b,d]furan-3-amine (50 mg, 
0.235 mmol) and HATU (107 mg, 0.282 mmol) were added at 0 °C. The resulting mixture was 
stirred at room temperature overnight. The mixture was diluted by DCM (10 mL), and the solution 
was washed with brine, and dried over anhydrous sodium sulfate. The solvent was evaporated 
under reduced pressure. The residue was purified by prep-HPLC to afford the desired product 22 
(8 mg, 7% yield) as white solid. 1H NMR (400 MHz, CDCl3): δ 9.59 (s, 1H), 8.71 (s, 1H), 7.87 (d, 
J = 7.6 Hz, 1H), 7.80 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.0 Hz, 1H), 7.29-7.42 (m, 5H), 4.30-4.33 
(m, 1H), 4.07 (s, 3H), 3.61-3.65 (m, 1H), 3.27-3.29 (m, 1H), 2.45 (s, 3H), 2.32-2.36 (m, 1H), 1.68-
1.70 (m, 1H), 1.60-1.67 (m, 2H). 13C NMR (400 MHz, CDCl3): δ 169.1, 156.8, 150.8, 145.6, 144.5, 
133.2, 130.0, 128.0, 127.4, 126.2, 124.6, 122.4, 119.8, 118.9, 111.7, 103.3, 101.6, 63.4, 57.0, 
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Methyl 1-(4-methylbenzyl)-5-oxopyrrolidine-2-carboxylate (23a). In an oven-dried 
round-bottom flask, methyl 5-oxopyrrolidine-2-carboxylate (500 mg, 3.02 mmol) was taken in dry 
THF (10 mL) and cooled to -30 °C under N2. To the reaction solution was added dropwise LiHMDS 
(701 mg, 4.19 mmol) at -30 ° C, and the mixture was stirred at this temperature for 1 h. A solution 
of 1-(bromomethyl)-4-methylbenzene (712 mg, 3.84 mmol) in THF was added dropwise to the 
reaction solution at -30 ° C. After naturally warming to room temperature, the resulting solution 
was stirred at room temperature for 4 h. The resulting mixture was diluted with ethyl acetate and 
the organic layers were washed with water. The organic phase was dried over anhydrous sodium 
sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with 
PE/EA (1:1 ) to afford the desired product (420 mg, 48% yield) as white solid. LC-MS (m/z) = 
248.1 [M+H]+.
1-(4-Methylbenzyl)-5-oxopyrrolidine-2-carboxylic acid (23b). To a solution of 23a (420 
mg, 1.70 mmol) in THF/H2O (4 mL:1 mL) was added LiOH (143 mg, 3.40 mmol). The resulting 
solution was stirred overnight at room temperature. The pH of the reaction solution was adjusted 
to a weak acidity with 1N hydrochloric acid. The resulting mixture was extracted with ethyl acetate 
(3 x 20 mL) and the organic layers were combined and washed with brine (30 mL). The organic 
phase was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue 
was the desired product (230 mg crude) as white solid. LC-MS (m/z) = 234.2 [M+H]+.
N-(2-Methoxydibenzo[b,d]furan-3-yl)-1-(4-methylbenzyl)-5-oxopyrrolidine-2-
carboxamide (23). Into a 50 mL round -bottom flask purged was placed a solution of 23b (55 mg 
crude, 0.235 mmol) in DCM (3 ml), and then DIEA (182 mg, 0.704 mmol), 2-
methoxydibenzo[b,d]furan-3-amine (50 mg, 0.469 mmol) and HATU (107 mg, 0.282 mmol) were 
added at 0 oC. The resulting mixture was stirred at room temperature overnight. The mixture was 
diluted by DCM (10 mL), and the solution was washed with brine, and dried over anhydrous 
sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified 
by prep-HPLC to afford the desired product (15 mg, 15% yield) as white solid. 1H NMR (400 MHz, 
CDCl3): δ 8.68 (s, 1H), 8.11 (s, 1H), 7.87 (d, J = 7.2 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.32-7.44 
(m, 3H), 7.10-7.16 (m, 4H), 5.13-5.17 (m, 1H), 3.94-4.02 (m, 5H), 2.67-2.74 (m, 1H), 2.44-2.52 
(m, 1H), 2.30-2.41 (m, 1H), 2.29 (s, 3H), 2.17-2.23 (m, 1H). 13C CMR (400 MHz, CDCl3): δ 175.6, 
169.2, 156.8, 150.7, 144.9, 137.7, 132.6, 129.5, 128.7, 126.5, 126.4, 124.4, 122.5, 119.8, 119.2, 
111.8, 103.8, 101.0, 61.5, 56.4, 45.6, 29.8, 23.6, 21.1. LC-MS (m/z) = 429.2 [M+H]+.
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N-(2-Methoxydibenzo[b,d]furan-3-yl)-5-oxopyrrolidine-2-carboxamide (24). Into a 50 
mL round -bottom flask purged was placed a solution of pyroglutamic acid (61 mg crude, 0.469 
mmol) in DCM (6 ml), and then DIEA (182 mg, 1.41 mmol), 2-methoxydibenzo[b,d]furan-3-amine 
(100 mg, 0.469 mmol) and HATU (214 mg, 0.563 mmol) were added at 0 oC. The resulting mixture 
was stirred at room temperature overnight. The mixture was diluted by DCM (20 mL), and the 
solution was washed with brine, and dried over anhydrous sodium sulfate. The solvent was 
evaporated under reduced pressure. The residue was purified by prep-HPLC to afford the desired 
product (15 mg, 10% yield) as white solid. 1H NMR (400 MHz, DMSO-d6): δ 9.43 (s, 1H), 8.46 (s, 
1H), 8.09 (d, J = 7.6 Hz, 1H), 7.99 (s, 1H), 7.84 (s, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.46 (t, J = 8.0 
Hz, 1H), 7.37 (t, J = 7.6 Hz, 1H), 4.44-4.47 (m, 1H), 3.99 (s, 3H), 2.33-2.40 (m, 1H), 2.21-2.30 (m, 
1H), 2.10-2.18 (m, 1H), 2.02-2.07 (m, 1H). 13C CMR (400 MHz, DMSO-d6): δ 178.1, 172.3, 156.4, 
150.0, 146.6, 127.6, 127.1, 124.6, 123.3, 121.1, 119.1, 112.0, 104.4, 103.3, 57.1, 56.7, 29.6, 26.0. 



































-carboxylate (25a). To a solution of tert-butyl 5-oxopyrrolidine-2-carboxylate (509 mg, 
2.75 mmol, 1.0 eq) in anhydrous THF (10 mL) at 0 oC, NaH (330 mg, 8.24 mmol, 3.0 eq) was 
added. The mixture was stirred for 15 min, and 4-(trifluoromethyl)benzene-1-sulfonyl chloride (739 
mg, 3.02 mmol, 1.1 eq) was added. The reaction mixture was stirred at room temperature for 2 h. 
Water was added and the mixture was extracted with EA. The organic phase was washed with 
water, brine, and dried over Na2SO4. It was filtered and concentrated to give the desired product 
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(0.5 g). 1H NMR (400 MHz, CDCl3): δ 8.24 (d, J = 8.3 Hz, 2H), 7.80 (d, J = 8.4 Hz, 2H), 4.79 (dd, 
J = 9.0, 2.6 Hz, 1H), 2.61 – 2.38 (m, 3H), 2.14 – 2.02 (m, 1H), 1.51 (s, 9H). LC-MS (m/z) = 394 
[M+H]+.
5-oxo-1-((4-(trifluoromethyl)phenyl)sulfonyl)pyrrolidine-2-carboxylic acid (25b). To 
a solution of 25a (81 mg, 0.206 mmol, 1.0 eq) in DCM (6.0 mL), TFA (1.5 mL) was added. The 
mixture was stirred at room temperature for 2 h. It was concentrated to obtain a crude product 
without purification. LC-MS (m/z) = 338 [M+H]+.
N-(2-methoxydibenzo[b,d]furan-3-yl)-5-oxo-1-((4-
(trifluoromethyl)phenyl)sulfonyl)pyrrolidine-2-carboxamide (25). To a solution of 25b (69 
mg, 0.206 mmol, 1.0 eq) and 2-methoxydibenzo[b,d]furan-3-amine (55 mg, 0.206 mmol, 1.0 eq) 
in pyridine (2.0 mL), POCl3 (10 drops) was added. The mixture was stirred at 65 °C overnight. 
Water was added and the mixture was extracted with EA. The organic phase was washed with 
water, brine, and dried over Na2SO4. It was filtered and concentrated. The residue was purified 
with prep-TLC to give the desired product (22 mg).  1H NMR (400 MHz, CDCl3): δ 8.64 (s, 1H), 
8.44 (s, 1H), 8.22 (d, J = 8.3 Hz, 2H), 7.87 (d, J = 7.7 Hz, 1H), 7.78 (d, J = 8.4 Hz, 2H), 7.57 (d, J 
= 8.2 Hz, 1H), 7.47 – 7.39 (m, 2H), 7.33 (dd, J = 10.9, 4.0 Hz, 1H), 5.00 (dd, J = 8.4, 2.3 Hz, 1H), 















































2,5-dichlorobenzenediazonium chloride (26a). 2,5-dichloroaniline (5.0 g, 30.86 mmol, 
1.0 eq) was dissolved in concentrated hydrochloric acid (8.75 mL) and ice (25 g) was added. 
When the mixture was cooled to 0 °C, saturated sodium nitrite (2.56 g, 37.04 mmol, 1.2 eq) 
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aqueous solution was added while keeping the temperature below 5 °C. After 15 min, resinous 
sediment was filtered, and the obtained diazonium salt solution was used into next step.
2',5'-dichloro-1,6-dihydro-[1,1'-biphenyl]-2,5-dione (26b). The diazonium salt solution 
26a was added dropwise into quinone (3.34 g, 30.86 mmol, 1.0 eq), AcONa (6.33 g, 77.15 mmol, 
2.5 eq), and water (120 mL) suspension while keeping the temperature at 15-20 °C. The reaction 
mixture was stirred for 2 h. The resulting solid was filtered.
8-chlorodibenzo[b,d]furan-2-ol (26c). 26b (2.0 g, 7.84 mmol, 1.0 eq) was mixed with
potassium hydroxide (440 mg, 7.84 mmol, 1.0 eq), sodium hydrosulphite (195 mg, 0.784 mmol, 
0.1 eq), and water (142 mg, 7.84 mmol, 1.0 eq) and heated to about 120 oC. Additional potassium 
hydroxide (880 mg, 15.68 mmol, 2.0 eq) was added while raising the temperature. On further 
heating, liquefaction set slowly in at 170 oC, and at 195 oC. The whole melt became thinly liquid 
and boiled. As soon as foaming was no longer observed, the reaction was finished. The melt was 
introduced into water, and extracted with EA. The organic layer was washed with water and brine, 
and dried with Na2SO4. It was filtered and concentrated. The residue was purified with silica gel 
column chromatography (PE:EA = 10:1-5:1), to give an orange solid (1.05 g). 1H-NMR (400 MHz, 
CDCl3): δ 7.83 (d, J = 1.6 Hz, 1H), 7.46-7.37 (m, 3H), 7.32-7.26 (m, 1H), 7.00-6.97 (m, 1H), 4.83 
(s, 1H). LC-MS (m/z) = 219 [M+H]+.
2-chloro-8-methoxydibenzo[b,d]furan (26d). To a solution of 26c (1.05 g, 4.82 mmol,
1.0 eq) in anhydrous THF (15 mL), NaH (386 mg, 9.64 mmol, 2.0 eq) was added under 0 oC. The 
mixture was stirred for 15 min, and CH3I (1.37 g, 9.64 mmol, 2.0 eq) was added. The reaction 
mixture was stirred at room temperature for 3 h. The mixture was diluted with water and extracted 
with EA. The organic phase was washed with water, brine, and dried over Na2SO4. It was filtered 
and concentrated to obtain the desired product (1.35 g). LC-MS (m/z) = 233 [M+H]+.
8-chloro-2-methoxy-3-nitrodibenzo[b,d]furan (26e). 26d (230 mg, 0.92 mmol, 1.0 eq)
was dissolved in acetic acid (3.0 mL), and nitric acid (70 mg, 1.12 mmol, 1.2 eq) was added. The 
mixture was stirred at room temperature overnight. The reaction mixture was mixed with water, 
and extracted with EA. The organic phase was washed with water, brine, and dried over Na2SO4. 
It was filtered and concentrated to obtain the crude product.
8-chloro-2-methoxydibenzo[b,d]furan-3-amine (26f). To crude 26e (255 mg, 0.92
mmol, 1.0 eq) in ethanol (12.0 mL) and aqueous NH3Cl (12.0 mL), iron powder (412 mg, 7.36 
mmol, 8.0 eq) was added. The mixture was stirred under reflux for 2 h. The reaction mixture was 
mixed with water, and extracted with EA. The organic phase was washed with water, brine, and 
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dried over Na2SO4. It was filtered and concentrated to obtain the crude product that was purified 
with prep-TLC to give the desired product (94 mg, yield 41.4%). LC-MS (m/z) = 248 [M+H]+.
N-(8-chloro-2-methoxydibenzo[b,d]furan-3-yl)-5-oxo-1-tosylpyrrolidine-2-
carboxamide (26). To a mixture of 26f (94 mg, 0.38 mmol, 1.0 eq) and 5-oxo-1-tosylpyrrolidine-
2-carboxylic acid (129 mg, 0.46 mmol, 1.2 eq) in pyridine (4.0 mL), POCl3 (20 drops) was added. 
The mixture was stirred at 65 °C for 5 h. 5% citric acid was added and the mixture was extracted 
with EA. The organic phase was washed with water, brine, and dried over Na2SO4. It was filtered 
and concentrated. The residue was purified with prep-TLC to give the desired product (25 mg). 
1H NMR (400 MHz, CDCl3): δ 8.66 (s, 1H), 8.58 (s, 1H), 7.95 (d, J = 8.3 Hz, 2H), 7.80 (d, J = 2.1 
Hz, 1H), 7.46 (d, J = 8.7 Hz, 1H), 7.36 (dd, J = 8.7, 2.1 Hz, 1H), 7.31 (d, J = 3.4 Hz, 2H), 7.29 (s, 
1H), 4.97 (dd, J = 8.3, 2.1 Hz, 1H), 4.02 (d, J = 4.7 Hz, 3H), 2.80 (m, 1H), 2.50 – 2.40 (m, 5H), 

















































2,4-dichlorobenzenediazonium chloride (27a). 2,4-dichloroaniline (2.0 g, 12.35 mmol, 
1.0 eq) was dissolved in concentrated hydrochloric acid (3.5 mL) and ice (10 g) was added. When 
the mixture was cooled to 0 oC, saturated sodium nitrite (1.02 g, 14.81 mmol, 1.2 eq) aqueous 
solution was added while keeping the temperature below 5 oC. After 15 min, resinous sediment 
was filtered, and the resulting diazonium salt solution was used in the next step.
2',4'-dichloro-1,6-dihydro-[1,1'-biphenyl]-2,5-dione (27b). The diazonium salt solution 
was added dropwise into quinone (1.33 g, 12.3 mmol, 1.0 eq), AcONa (2.5 g, 30.75 mmol, 2.5 
eq), and water (50 mL) suspension while keeping the temperature at 15-20 °C. The reaction 
mixture was stirred for 2 h. The resulting solid was filtered.
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7-chlorodibenzo[b,d]furan-2-ol (27c). 27b (1.0 g, 3.92 mmol, 1.0 eq) was mixed with 
potassium hydroxide (220 mg, 3.92 mmol, 1.0 eq), sodium hydrosulphite (97 mg, 0.392 mmol, 
0.1 eq), and water (7.1 mg, 3.92 mmol, 1.0 eq) and heated to about 120 oC. Additional potassium 
hydroxide (440 mg, 7.84 mmol, 2.0 eq) was added while raising the temperature. On further 
heating, liquefaction set slowly in at 170 oC, and at 195 oC. The whole melt became thinly liquid 
and boiled. As soon as foaming was no longer observed, the reaction was finished. The melt was 
added into water, and the mixture was extracted with EA. The organic layer was washed with 
water and brine, and dried with Na2SO4. It was filtered and concentrated. The residue was purified 
with silica gel column chromatography (PE:EA = 10:1-5:1), to give an orange solid (110 mg). 1H 
NMR (400 MHz, CDCl3): δ 7.78 (d, J = 8.3 Hz, 1H), 7.54 (d, J = 1.7 Hz, 1H), 7.42 (d, J = 8.8 Hz, 
1H), 7.33 (d, J = 2.5 Hz, 1H), 7.30 (dd, J = 8.3, 1.8 Hz, 1H), 6.96 (dd, J = 8.8, 2.6 Hz, 1H), 4.77 
(s, 1H). LC-MS (m/z) = 219 [M+H]+.
7-chloro-2-methoxydibenzo[b,d]furan (27d). To a solution of 27c (110 mg, 0.505 mmol, 
1.0 eq) in anhydrous THF (15 mL), NaH (24 mg, 1.01 mmol, 2.0 eq) was added under 0 oC. The 
mixture was stirred for 10 min, and CH3I (143 mg, 1.01 mmol, 2.0 eq) was added. The reaction 
mixture was stirred at room temperature for 1 h. Water was added, and the mixture was extracted 
with EA. The organic phase was washed with water, brine, and dried over Na2SO4. It was filtered 
and concentrated to obtain the desired product (130 mg). 1H NMR (400 MHz, CDCl3): δ 7.81 (d, 
J = 8.3 Hz, 1H), 7.55 (d, J = 1.7 Hz, 1H), 7.46 (d, J = 8.9 Hz, 1H), 7.37 (d, J = 2.6 Hz, 1H), 7.31 
(dd, J = 8.3, 1.8 Hz, 1H), 7.05 (dd, J = 8.9, 2.6 Hz, 1H), 3.91 (s, 3H). LC-MS (m/z) = 233 [M+H]+.
7-chloro-2-methoxy-3-nitrodibenzo[b,d]furan (27e). To a solution of 27d (130 mg, 0.56 
mmol, 1.0 eq) in acetic acid (3.0 mL), nitric acid (70 mg, 0.67 mmol, 1.2 eq) was added. The 
mixture was stirred at room temperature overnight. The reaction mixture was mixed with water, 
and extracted with EA. The organic phase was washed with water, brine, and dried over Na2SO4. 
It was filtered and concentrated to obtain the crude product used in the next step without 
purification.
7-chloro-2-methoxydibenzo[b,d]furan-3-amine (27f). To a solution of crude 27e (155 
mg, 0.56 mmol, 1.0 eq) in ethanol (6.0 mL) and aqueous NH3Cl (6.0 mL), iron powder (251 mg, 
4.48 mmol, 8.0 eq) was added. The mixture was stirred under reflux for 2 h. The reaction mixture 
was mixed with water, and extracted with EA. The organic phase was washed with water, brine, 
and dried over Na2SO4. It was filtered and concentrated. The residue was purified with prep-TLC 
to give the desired product (45 mg). 1H NMR (400 MHz, CDCl3): δ 7.65 (d, J = 8.2 Hz, 1H), 7.46 
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(d, J = 1.7 Hz, 1H), 7.24 (dd, J = 8.3, 1.7 Hz, 1H), 7.22 (s, 1H), 6.88 (s, 1H), 4.23 – 4.04 (m, 2H), 
3.96 (s, 3H). LC-MS (m/z) = 248 [M+H]+.
N-(7-chloro-2-methoxydibenzo[b,d]furan-3-yl)-5-oxo-1-tosylpyrrolidine-2-carboxamide 
(27). To a solution of 27f (45 mg, 0.182 mmol, 1.0 eq) and 5-oxo-1-tosylpyrrolidine-2-carboxylic 
acid (62 mg, 0.218 mmol, 1.2 eq) in pyridine (2.0 mL), POCl3 (20 drops) was added. The mixture 
was stirred at 65 °C for 4 h. 5% citric acid was added, and the mixture was extracted with EA. 
The organic phase was washed with water, brine, and dried over Na2SO4. It was filtered and 
concentrated. The residue was purified with prep-TLC to give the desired product (15 mg). 1H 
NMR (400 MHz, CDCl3): δ 8.66 (s, 1H), 8.56 (s, 1H), 7.94 (d, J = 8.3 Hz, 2H), 7.77 (d, J = 8.3 Hz, 
1H), 7.57 (d, J = 1.6 Hz, 1H), 7.37 (d, J = 3.7 Hz, 1H), 7.31 (dd, J = 12.0, 5.2 Hz, 3H), 4.94 (dd, J 
= 8.3, 2.0 Hz, 1H), 4.04 (s, 3H), 2.80 (m, 1H), 2.51 – 2.30 (m, 6H). LC-MS (m/z) = 513 [M+H]+.
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Figure 1. Identification of druggable targets implicated in glioblastoma multiforme (GBM). 
(a) Workflow used to identify GBM-specific druggable targets through integration of 
genomic RNA-seq, somatic mutation, protein-protein interaction network, and protein 
structure data. Small-molecule compounds were screened against these pockets to 
identify compounds that could target proteins implicated in GBM. (b) Differential 
expression analysis of 169 tumor and 5 normal GBM RNA-seq samples from TCGA. Mean 
fitted counts for each gene are shown on the x- and y-axis, respectively. (c) Protein-protein 
interaction subnetwork of GBM-specific targets. Proteins are shown as squares if there is 
a solved human crystal structure available or as circles otherwise. Proteins with a 
druggable binding pocket on an associated structure are colored red or white otherwise. 
(d) Degree (number of edges) versus betweenness centrality for GBM-specific targets 
from (c). (e) Waterfall plot of each compound’s number of predicted GBM-specific targets 
using an SVR-KB cutoff of 10 nM. (f) Histogram plot showing the percentage of 
compounds predicted to bind to the number of GBM-specific targets using an SVR-KB 
cutoff of 10 nM.
Figure 2. Screening compounds against GBM43 leads to the identification of 1 (IPR-2025). 
(a) Compounds that were predicted to bind GBM-specific proteins were screened at a 
concentration of 25 µM with 0.5% DMSO for their effect on cell viability of GBM43 
spheroids (mean ± s.d.; n = 3). Culture medium, culture medium with 1% DMSO, a TGV 
cocktail (200 µM temozolomide, 12.5 µM ipatasertib/GDC-0068 [pan AKT inhibitor], 12.5 
µM voxtalisib/VOX [PI3K/mTOR inhibitor]), CCNU (50 µM lomustine) are also shown. (b) 
Structure of 1, which emerged from screening top candidates. (c) Stability of 1 in buffer 
(0.5 mL of a 1 mL incubation) using high performance liquid chromatography (HPLC). (d) 
Concentration-dependent study of 1 in glioblastoma multiforme (GBM), normal, and 
pancreatic adenocarcinoma (PDAC) cell lines (mean ± s.d.; n = 3). (e) IC50 values from 
fitting concentration-dependent curves from (d). NI corresponds to no inhibition. (f) 
Concentration-dependent study of CCNU (lomustine) in GBM43 and GBM10 spheroids. 
(g) Tube formation of brain microvascular endothelial cells treated with 1 compared to 
DMSO control. (h) Concentration-dependent angiogenesis assay evaluating tube 
formation of 1. Compound 1 has an approximate IC50 of 0.1 µM.
Figure 3. Compound activities of resynthesized 1 (IPR-2025) and synthesized derivatives. 
Compound activity of 1 and six synthesized derivatives in the three GBM cell lines GBM43, 
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GBM10, and SJ-GBM2. The molecular structures, calculated physicochemical properties, 
and GBM IC50s are provided in the table to the right. NI and ND denote ‘No Inhibition’ and 
‘Not determined’, respectively.
Figure 4. RNA-Seq of 1 (IPR-2025) treated GBM43 cells. (a) Volcano plot of fold change versus 
log-transformed significance of GBM43 cells treated with 10 µM of 1 versus control. 
Differentially expressed genes are identified using a log2 fold change cutoff of 1. (b) The 
top 15 most overexpressed and underexpressed genes identified in cells treated with 
GBM43. (c) The most similar 30 perturbagens to the gene signature of treated GBM43 
identified using the L1000 platform. Perturbagens are rank-ordered using the median τ 
statistic across nine cell lines, and are classified into gene knockdown (KD), 
overexpression (OE), and compounds (CP).
Figure 5. Thermal proteome profiling of 1 (IPR-2025) treated GBM43 Cells. (a) GBM43 cells 
treated with 10 µM 1 and untreated cells were serially heated to six different temperatures 
for thermal proteome profiling. Proteins were identified and quantified using mass 
spectrometry. Melting curves were fitted for each protein to determine the shift in melting 
temperature between untreated and treated proteins (ΔTm). The panel shows a scatterplot 
of the calculated melting temperature (Tm) in individual proteins between vehicle and 
compound-treated experiments. (b) The list of proteins found to have the largest increase 
in melting temperature when treated with 1 (ΔTm ≥ 3 °C). (c) The list of proteins found to 
have the largest decrease in melting temperature when treated with 1 (ΔTm ≤ -3 °C). (d) 
Comparison of proteins implicated by 1. The SVR-KB predicted targets (orange), 
differentially expressed genes (overexpressed: yellow, underexpressed: blue-purple), 
most similar perturbagens from L1000 analysis of differentially expressed RNA-seq genes 
(KD: purple, OE: blue), and proteins from thermal proteome profiling (ΔTm ≥ 3 °C: green, 
ΔTm ≤ -3 °C: red) are represented as nodes. Node borders are black if there is a solved 
human crystal structure available or uncolored otherwise. Nodes appear as rectangles if 
there is a druggable binding pocket on the associated protein or circles otherwise. 
Connections between nodes are built using STRING. Edges between connected proteins 
are filtered by confidence (STRING confidence: high, score ≥ 0.7) and colored based on 
the source of evidence (co-expression: black, database: blue, experimental: magenta). 
Unconnected nodes are omitted. 
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The supporting information is available free of charge at http://pubs.acs.org: Protein targets and 
compounds identified from integrative analysis, compound structures and physicochemical 
properties, concentration-dependent curves against GBM spheroids, cell viability studies, thermal 
proteome profiling curves, and possible mechanism for reaction of 1.
 Supporting data (supplementary figures and tables) (PDF)
 Table S1. GBM protein targets identified from analysis of TCGA genomic and mutation,
PPI network, and PDB structural data (XLSX)
 Table S2. Compounds identified from virtual screening against TCGA GBM (XLSX)
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Table 1. Predicted protein targets of 1 (IPR-2025)









PLK1 Serine/threonine-protein kinase PLK1 Ser/Thr protein kinase 15 1.70E-03 3.3 9
NCF1 Neutrophil cytosol factor 1 - 9 1.70E-04 2.3 6
PNP Purine nucleoside phosphorylase PNP/MTAP phosphorylase 2 0.00E+00 1.4 6
DNA-Binding Site
EXO1 Exonuclease 1 XPG/RAD2 endonuclease 10 3.40E-04 3.7 14
TOP2A DNA topoisomerase 2-alpha Type II topoisomerase 3 2.50E-05 7.2 10
Beta-Propeller
CDC20 Cell division cycle protein 20 homolog WD repeat CDC20/Fizzy 8 3.10E-04 3.5 9
GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 WD repeat G protein beta 29 4.60E-03 2.0 9
ITGA5 Integrin alpha-5 Integrin alpha chain 2 1.50E-05 3.0 11
RACK1 Receptor of activated protein C kinase 1 WD repeat G protein beta 5 1.10E-04 1.4 6
Allosteric Site near Protein-Protein Interaction Interface
NCF2 Neutrophil cytosol factor 2 NCF2/NOXA1 8 6.50E-04 2.3 9
NEDD4 E3 ubiquitin-protein ligase NEDD4 - 15 1.10E-03 2.0 15
PYGL Glycogen phosphorylase, liver form Glycogen phosphorylase 3 0.00E+00 3.2 19
Allosteric Site near Enzymatic Nucleoside
KIF11 Kinesin-like protein KIF11 Kinesin 4 8.40E-06 2.8 6
TAP1 Antigen peptide transporter 1 ABC transporter 2 2.40E-04 2.4 12
Other Allosteric Site
ACE Angiotensin-converting enzyme Peptidase M2 1 0.00E+00 1.9 19
CENPE Centromere-associated protein E Kinesin 6 7.50E-05 2.8 17
EZH2 Histone-lysine N-methyltransferase EZH2 Histone-lysine methyltransferase 6 2.00E-04 4.5 10
FLNA Filamin-A Filamin 34 7.90E-03 2.5 20
GUSB Beta-glucuronidase Glycosyl hydrolase 2 0.00E+00 2.0 7
MMP2 72 kDa type IV collagenase Peptidase M10A 4 7.40E-04 3.9 12
MMP9 Matrix metalloproteinase-9 Peptidase M10A 4 1.60E-08 7.3 8
NR5A2 Nuclear receptor subfamily 5 group A member 2 Nuclear hormone receptor 6 3.10E-05 4.4 6
NRP1 Neuropilin-1 Neuropilin 2 4.10E-07 1.8 18
PLA2G4A Cytosolic phospholipase A2 - 1 0.00E+00 1.6 7
SHMT2 Serine hydroxymethyltransferase, mitochondrial SHMT 2 3.60E-06 2.0 7
SPARC SPARC SPARC 1 0.00E+00 3.1 7
TLR2 Toll-like receptor 2 Toll-like receptor 3 4.40E-05 2.0 17
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